



London's Frontier Innovation Board
Thursday 27th November 2025, 3pm – 5pm
London & Partners, 169 Union Street, London SE1 0LL & MS Teams

Agenda

Item	Title	Paper	Lead	Time
1.	Welcome and introductions		Chair	15 mins
2.	Apologies			
3.	Terms of Reference	Annex A: Draft ToR	Chair	10 mins
4.	LIPF: Overview and Proposed Process	Annex B: LIPF Overview	GLA	45 mins
5.	LIPF: London Funding Priorities		Chair	45 mins
6.	Dates of Future Meetings		Chair	5 mins
7.	AOB		Chair	

Attendees:

Laura Citron OBE (Chair) (LC)
Howard Dawber OBE HD
Alan Thompson (AT)
Amanda Wolthuizen (AW)
Jodie Eastwood (JE)
Professor Kevin Fenton CBE (KF)
Rikesh Shah (RS)
Tony Clements (TC)
Eddie Copeland (EC)
Shazia Hussain (SH)
Karen Skinner (KS)
Alex Conway (AC)
Saul Klein OBE (SK)
Professor Shitij Kapur (SK)
Professor Nilay Shah OBE (NS)
Caroline Clarke (CC)
Anne Glover (AG)

Alex Conway, GLA (presenting)
Dr. Angela Kukula (AK) observer

Apologies

Patrick Chinnery, Medical Research Council, UKRI*
Eddie Copeland, LOTI
Sir Mark Caulfield, QMUL
Dr. Noorzaman Rashid, CEME

Sandy Tung (ST) observer
Fergus Moffatt (FM)
Jordan McCaul (JM) minute taker

1. Welcome and Introductions

1.1 LC opened the meeting and welcomed all attendees both in person and online.

2. Apologies

2.1 Apologies were noted.

3. Terms of Reference

3.1 Paper: Annex A – Draft ToR

3.2 LC introduced the Terms of Reference and asked all members to review and raise any objections or suggested amendments. No objections were raised during the meeting.

3.3 Decision: The Board approved the Terms of Reference.

4. LIPF: Overview and Proposed Process

4.1 Paper: Annex B – LIPF Overview

4.2 AC provided an overview of the Local Innovation Partnership Fund (LIPF), noting that funding was announced in the July spending review and must be deployed by next summer.

4.3 Proposed roles and responsibilities of the GLA were outlined, including that the GLA should act as Lead Bidder and Local Anchor Entity.

4.4 LC emphasized that being a Board member does not prevent organisations from bidding, but members must not use the position to influence outcomes and should declare where there is a conflict of interest.

4.5 Decision: The Board approved the GLA as Lead Bidder and Local Anchor Entity.

5. Funding Priorities Discussion

5.1 Match Funding: The Board discussed eligibility of match-funding sources. Clarification from UKRI is required on match eligibility of international sources of funding, commercial contracts, and public sector contracts.

5.2 Action: DL to follow up on match-funding eligibility.

5.3 The Board was in broad agreement that it should take a targeted approach and focus on breakout-stage companies.

6. Sector and Technology Focus

6.1 The Board reviewed the proposed priority sectors, drawing on the Industrial Strategy, the London Growth Plan, and the Science and Technology Framework.

6.2 The Board agreed on which sectors and technologies should be targeted, noting that clarification is still required on whether advanced manufacturing and defense should be included within scope.

7. Type of Intervention

7.1 Interventions should focus on access to market demand and helping companies secure commercial contracts. Examples include:

- Procurement pathways
- Aggregated demand
- Market-making and offtake agreements
- Open innovation
- Access to international buyers
- Debt/equity financing linked to market access

7.2 The Board discussed enabling strategic buyers and leveraging public-sector procurement. Health-related procurement opportunities were highlighted as particularly impactful.

9. Coordination

9.1 The board agreed projects should connect clusters within London and, where appropriate, connect London clusters with other parts of the UK.

10. Minimum Project Size

10.1 The Board agreed to a minimum £2m grant, matched with £4–£6m additional funding.

11. Impact

11.1 The Board did not reach a conclusion on whether to include an explicit impact criterion and agreed to revisit this at project review stage.

11.2 Action: GLA to amend the Registration of Interest form in-line with the Board discussion and circulate it to members, ahead of sharing with broader stakeholders.

12. Dates of Future Meetings

12.1 The Chair noted the importance of providing clear but not overly restrictive guidance before applications open.

13. Any Other Business

13.1 No further business was raised.